By Digifin Pty Ltd · About this coverage
Key Points
- FDA 510(k) clearance received for CT-based BMD on MDCT supine scans
- Described as first of two clearances needed for SaaS bone health products
- Next step is FDA clearance to extend BMD to HiRise weight bearing CT
- SaaS revenue launch tied to achieving the HiRise BMD clearance
- Longer-term surgical planning integration remains subject to further clearances
About CurveBeam AI (ASX:CVB)
CurveBeam AI Limited is an ASX-listed medical imaging company with its corporate office in Melbourne and global operations headquarters in Hatfield, Pennsylvania. It develops, manufactures and sells specialised CT scanners and AI-enabled clinical assessment software for musculoskeletal conditions, including the HiRise weight bearing CT system.
CurveBeam AI (ASX:CVB) has received FDA 510(k) clearance for its CT-based Bone Mineral Density technology, establishing a regulatory base for later BMD SaaS applications across its CT portfolio.
The clearance covers CT-based BMD using multidetector CT supine scans. The company says this is the first of two necessary clearances to take its SaaS-based bone health products to market. Next it will pursue FDA clearance to extend BMD measurement to the HiRise platform for weight bearing, standing CT BMD, and a SaaS revenue launch once that HiRise clearance is achieved. Longer term it sees potential to integrate quantitative BMD data into advanced and robotic-assisted orthopaedic surgical planning workflows, subject to appropriate regulatory clearances and clinical validation. Integrating BMD into the CT examination is presented as a way to provide quantitative bone information without a separate DXA appointment for patients already undergoing orthopaedic CT.
SaaS revenue from BMD is contingent on the further HiRise clearance. Timing, pathway and clinical evidence requirements for that submission are not fixed in this release.
Source: CurveBeam AI Limited (ASX:CVB), 15 September 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.